Vergoeding 2019-2023 voor ATC-subgroep L04AB : Tumornecrosefactor-alfa-antagonisten
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021* | 2022* | 2023* | |
|---|---|---|---|---|---|
| L04AB01 Etanercept | 67.231.482 | 41.215.022 | 33.043.474 | 23.146.388 | 21.541.290 |
| L04AB02 Infliximab | 90.148.121 | 70.410.390 | 63.349.357 | 52.463.936 | 48.267.871 |
| L04AB04 Adalimumab | 89.678.353 | 64.954.179 | 63.223.204 | 55.440.344 | 49.265.552 |
| L04AB05 Certolizumab pegol | 12.909.900 | 12.073.594 | 12.331.731 | 12.120.148 | 12.675.316 |
| L04AB06 Golimumab | 19.653.586 | 17.572.823 | 16.346.823 | 15.321.985 | 14.581.584 |
| Totaal | 279.621.442 | 206.226.008 | 188.294.590 | 158.492.800 | 146.331.613 |